F-1/A: Kazia Therapeutics Amends Resale Prospectus, Boosts Cash

Kazia Therapeutics Limited filed an F-1/A registration statement for the resale of up to 232,956 American Depositary Shares by selling shareholders, following a recent $46.5 million private placement and regaining Nasdaq compliance.

Summary

• The filing is an Amendment No. 1 to Form F-1 Registration Statement for Kazia Therapeutics Limited, primarily for the resale of up to 232,956 American Depositary Shares (ADSs) by selling shareholders, representing 116,478,000 Ordinary Shares.
• The company will not receive any proceeds from the sale of the Offered ADSs by the Selling Shareholders, except for nominal proceeds of approximately $20.45 if all pre-funded warrants are exercised for cash.
• A private placement on December 2, 2025, generated approximately $46.5 million in net proceeds, which is expected to extend the company's cash runway into the second half of 2028.
• Kazia Therapeutics regained compliance with Nasdaq Listing Rule 5550(b)(1) (minimum stockholders' equity requirement) on December 18, 2025, leading to the cancellation of a delisting hearing.
• The company is an oncology-focused biotechnology firm with lead development candidate paxalisib (for glioblastoma and advanced breast cancer) and EVT801 (a selective inhibitor of vascular endothelial growth factor receptor 3).
• The ADSs are listed on the Nasdaq Capital Market under the symbol KZIA, with a last reported sale price of $9.98 per ADS on December 18, 2025.

Sentiment

Score: 7

Explanation: The significant capital raise and regaining Nasdaq compliance are strong positives, addressing immediate financial and listing concerns. However, the underlying business (biotech drug development) remains high-risk, and the going concern warning from the auditor (though incorporated by reference) indicates ongoing financial challenges. The filing itself is primarily for resale, not a new operational update.

Positives

• Regained compliance with Nasdaq Listing Rule 5550(b)(1) as of December 18, 2025, resolving a previous non-compliance issue and avoiding delisting.
• Successfully completed a private placement on December 3, 2025, raising approximately $46.5 million in net proceeds.
• The recent capital raise is expected to extend the company's cash runway into the second half of 2028, enhancing financial stability.
• Maintains a portfolio of development candidates in oncology, including lead candidate paxalisib and second asset EVT801, indicating ongoing R&D efforts.

Negatives

• Previously received a Nasdaq staff determination letter on November 12, 2025, for failing to meet the $35 million Market Value of Listed Securities (MVLS) requirement.
• The independent auditor's report (incorporated by reference) contains an explanatory paragraph regarding the company's ability to continue as a going concern, highlighting financial fragility.
• The market price of the ADSs has been and is expected to remain highly volatile.
• If the market price of ADSs falls and remains below $5.00 per share, shareholders will be unable to use them as collateral for margin accounts, potentially depressing demand and increasing volatility.

Risks

• The market price of the ADSs has been and will likely continue to be volatile due to factors such as unacceptable toxicity findings in trials, lack of efficacy, competitor innovations, changes in financial estimates, variations in operating results, expiration of licenses, regulatory climate changes, and economic conditions.
• Failure to meet Nasdaq's continued listing requirements could result in a delisting of ADSs, negatively affecting price and liquidity.
• Raising additional capital may cause dilution to existing shareholders, restrict operations, or require relinquishing valuable rights.
• Future sales or issuances of ADSs in the public markets, or the perception of such sales, could depress the trading price of the ADSs.
• Reliance on the Depositary to exercise voting rights and receive distributions on ADSs may limit ADS holders' ability to vote timely or receive certain distributions.
• No current intention to pay dividends on securities, meaning investment return depends solely on ADS price appreciation.
• Potential classification as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, which could lead to adverse tax consequences for U.S. holders.
• Difficulty enforcing civil liabilities against non-U.S. resident directors or the company in U.S. courts due to Australian incorporation and non-U.S. residency of directors.
• Adverse economic changes in Australia, the U.S., EU, or globally could materially affect the business or results of operations.
• Securities class action litigation may be instituted following periods of volatility, incurring substantial costs and diverting management's attention.

Future Outlook

The company expects the net proceeds from the December 2025 Private Placement, combined with existing cash and cash equivalents, to extend its cash runway into the second half of 2028. It plans to continue developing and potentially commercializing its product candidates, including initiating and completing preclinical studies and clinical trials, with anticipated data availability and regulatory filings.

Industry Context

Kazia Therapeutics operates in the highly competitive and rapidly evolving oncology-focused biotechnology industry. The development of novel therapies for severe conditions like glioblastoma and advanced breast cancer is a capital-intensive and high-risk endeavor. The need for frequent capital raises, as evidenced by this filing, is typical for biotech companies in the development stage. The sector is characterized by significant stock price volatility, often driven by clinical trial results, regulatory milestones, and competitive landscape changes.

Related Party Transactions

• Alumni Capital LP, a selling shareholder, has engaged in multiple transactions with the company, including the Alumni ELOC Purchase Agreement and participation in the January 2025 and December 2025 Private Placements.
• Pointillist Global Macro Series of Pointillist Partners, LLC also participated in the December 2025 Private Placement.

Stakeholder Impact

• **Shareholders**: Potential for future dilution from capital raises; continued volatility in ADS price; reliance on the Depositary for voting and distributions; no expected dividends; regaining Nasdaq compliance is positive for market access and liquidity.
• **Selling Shareholders**: This filing facilitates their ability to resell previously acquired ADSs and warrants, providing liquidity for their investments.
• **Employees**: Continued operations and drug development efforts are supported by the extended cash runway, but the 'going concern' note implies underlying financial fragility.
• **Customers/Patients**: Continued development of oncology candidates (paxalisib, EVT801) offers potential future therapies for serious diseases.
• **Creditors**: The significant capital raise improves the company's cash position, reducing immediate liquidity risk.

Next Steps

• Selling Shareholders may offer or resell the Offered ADSs from time to time.
• The company will continue to develop and potentially commercialize its product candidates, including conducting preclinical studies and clinical trials.
• The company intends to make available information for U.S. holders to make a Qualified Electing Fund (QEF) election if it is determined to be a Passive Foreign Investment Company (PFIC).
• The company will file post-effective amendments to the registration statement as required by the Securities Act of 1933.

Key Dates

Recommendation

The successful capital raise of $46.5 million and the regaining of Nasdaq compliance are significant positive developments that alleviate immediate financial and listing pressures, justifying a 'hold' position for existing investors. These actions provide a much-needed extension to the cash runway into the second half of 2028. However, the company's core business in oncology drug development remains inherently high-risk, with a history of stock price volatility and an auditor's 'going concern' note. While the immediate threats are mitigated, long-term success hinges on uncertain clinical trial outcomes and regulatory approvals. New investors should approach with caution due to the speculative nature of biotech and the potential for further dilution.

Keywords

Kazia Therapeutics, Biotechnology, Oncology, SEC filing, F-1/A, ADS resale, Private Placement, Nasdaq compliance, Capital raise, Paxalisib, EVT801, Warrants, KZIA, Foreign Private Issuer